Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study
Andrew Dean, Sanjeev Gill, Mark D. McGregor, Vy Broadbridge, Harri A. Järveläinen, Timothy Price
Topics & Concepts
MedicineGemcitabineInternal medicineTolerabilityOncologyPancreatic cancerAdverse effectPopulationResponse Evaluation Criteria in Solid TumorsHazard ratioPhases of clinical researchClinical trialChemotherapyCancerConfidence intervalEnvironmental healthCell Adhesion Molecules ResearchAngiogenesis and VEGF in CancerImmunotherapy and Immune Responses